SMYD2 and breast carcinoma: Altogether, these data validated SMYD2 as a driver of breast cancer metastases and supported the molecular mechanisms of action of the SMYD2-BCAR3-FMNLs signaling in the regulation of cell motility and invasion (Fig. 7j).